Bharat BioTech’s Covid-19 vaccine, Covaxin, has become the second vaccine to secure recommendation for restricted emergency use from a government-appointed expert panel in India. This comes a day after the panel made a similar recommendation for Covishield, the vaccine developed by Oxford University and AstraZenca.
An expert panel of the Central Drugs Standard Control Organisation (CDSCO) on Saturday recommended Covaxin should be granted restricted emergency use in India.
However, a final decision on whether these two vaccines should be given emergency use approval in India will be taken by the Drugs Controller General of India (DCGI).
Apart from the recommendations for Covaxin and Covishield, the Subject Expert Committee (SEC) of CDSCO also recommended Phase-III trials of the vaccine candidate that is being developed by Cadila Healthcare Ltd.
The panel’s recommendation for emergency use for the two vaccines paves the way for rollout of Covid-19 vaccines in India.